Amplia Therapeutics (ASX:ATX) produced around 13 kilograms of its narmafotinib drug candidate for the treatment of cancer to the required purity and quality specifications after the completion of a large-scale manufacturing campaign, according to a Thursday Australian bourse filing.

The next step will involve converting the manufactured drug substance, or the active pharmaceutical ingredient, into oral capsules for use in ongoing and upcoming clinical trials.

Narmafotinib is a focal adhesion kinase inhibitor.

Its shares rose 7% in recent trading on Thursday.